NSE · IOLCP · Pharmaceuticals
IOL Chemicals & Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹619 Cr with net profit ₹53 Cr — a 8.59% net margin, versus 3.55% the period before.
Shareholding
As of 2026-06-30
- Promoter62.28%
- Public32.42%
- FII4.87%
- DII0.43%
1,19,311 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.67× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #36 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,72,645 Cr | 38.03 | 5.66 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,18,430 Cr | 213.39 | 3.44 | 11.27% | 14% |
| Lupin Limited | ₹1,10,979 Cr | 69.69 | 4.94 | 23.76% | 19.4% |
| Zydus Lifesciences Ltd. | ₹1,10,623 Cr | 20.36 | 4.08 | 18.59% | 18.86% |
| Mankind Pharma Limited | ₹1,08,023 Cr | 194.61 | 6.62 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,078 Cr | 343.98 | 18.11 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹94,560 Cr | 427.51 | 2.5 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹91,290 Cr | 99.1 | 2.41 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,586 Cr | 543.42 | 2.04 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,943 Cr | 287.43 | 4.92 | 16.66% | 15.65% |
| IOL Chemicals & Pharmaceuticals Ltd.(this company) | ₹4,349 Cr | 81.86 | 2.42 | 7.65% | 5.94% |
AI analysis
AI-generated · google/gemini-2.5-flashIOL Chemicals & Pharmaceuticals Ltd. is listed with a market capitalization of Rs 4354 Cr. The company reported a revenue of Rs 2101.62 Cr. Its debt-to-equity ratio is 0.05. Earnings per share (EPS) stands at Rs 3.44, with a Price-to-Earnings (PE) ratio of 17.79. Return on equity (ROE) is 6.1%, and return on capital employed (ROCE) is 10.29%.
Positives
- +The debt-to-equity ratio is low at 0.05, indicating strong financial health.
- +Promoter pledge is 0%, suggesting no shares held by promoters are encumbered.
- +Revenue increased from Rs 523.3 Cr in Dec 2024 to Rs 619.45 Cr in Mar 2026.
Negatives
- −The company's Return on Equity (ROE) is 6.1%, which may be considered low.
- −The company is under LT-ASM surveillance, specifically ASM 1.
- −Net profit declined from Rs 33.93 Cr in Jun 2025 to Rs 20.58 Cr in Dec 2025.
- −No dividend yield information is disclosed.
Financial Performance
For the period ending Mar 2026, IOL Chemicals & Pharmaceuticals Ltd. recorded a revenue of Rs 619.45 Cr and a net profit of Rs 53.16 Cr. This follows a revenue of Rs 580.39 Cr and a net profit of Rs 20.58 Cr in Dec 2025. In Jun 2025, the company's revenue was Rs 551.69 Cr with a net profit of Rs 33.93 Cr. The company's EBITDA for Mar 2026 was Rs 74.02 Cr.
Profitability & Returns
The company's Return on Equity (ROE) is 6.1%, and its Return on Capital Employed (ROCE) is 10.29%. The Earnings Per Share (EPS) is Rs 3.44. The Price-to-Earnings (PE) ratio is 17.79. These figures indicate the company's efficiency in generating profits relative to its equity and capital employed.
Balance Sheet
IOL Chemicals & Pharmaceuticals Ltd. has a low debt-to-equity ratio of 0.05, suggesting a limited reliance on borrowed capital. The book value per share is Rs 57.49. The company's market capitalization stands at Rs 4354 Cr.
Ownership & Pledges
As of June 30, 2026, promoters held 62.28% of the shares. Public shareholding was 32.42%, while FIIs held 4.87% and DIIs held 0.43%. Institutional holding stood at 5.31%. There are no promoter shares pledged, as indicated by a promoter pledge percentage of 0%.
Regulatory & Surveillance
IOL Chemicals & Pharmaceuticals Ltd. is currently under LT-ASM surveillance, specifically in ASM Stage 1. This involves specific measures due to its inclusion in the Long Term Additional Surveillance Measure framework.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to IOL Chemicals & Pharmaceuticals Ltd.share price & fundamentals